Vysov-M 50/1000 Mg Tablet (Vildagliptin/Metformin)

Description

Introduction

Vysov-M 50/1000 Mg Tablet contains vildagliptin 50 mg and metformin 1000 mg in an oral tablet. It is presented for the management of type 2 diabetes. These ingredients lower blood glucose through different mechanisms. A healthcare professional determines whether this combination and strength are appropriate in the context of other medicines, kidney and liver function, and blood glucose results.

What Is It?

Vysov-M is a combination of two glucose-lowering medicines. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while metformin is a biguanide. The tablet is intended for use as part of type 2 diabetes management, alongside diet and physical activity. It is not a treatment for type 1 diabetes or diabetic ketoacidosis. The exact tablet coating, inactive ingredients and metformin salt in this particular product have not been verified; ask a pharmacist if these details matter to you.

How Does It Work?

Vildagliptin inhibits DPP-4, an enzyme that breaks down incretin hormones. Incretins help the pancreas release insulin when blood glucose rises and help regulate glucagon, a hormone involved in glucose production. Metformin mainly reduces glucose production by the liver. The combined effect can improve blood glucose control, but individual responses differ. Neither ingredient replaces the wider care needed for type 2 diabetes.

Common Uses

Vildagliptin and metformin combinations are used when metformin alone does not provide enough blood glucose control, or when the two ingredients are already being taken as separate medicines. They may also be used with other glucose-lowering treatments when further control is needed. These are uses of the ingredient combination; the suitability of Vysov-M for any particular treatment plan needs professional assessment. No claim about this brand’s Australian approval status is made here.

Available Strengths

This family is available in 500 mg, 1000 mg.

Key Features

• Each tablet is identified as containing vildagliptin 50 mg and metformin 1000 mg.
• It provides two glucose-lowering ingredients in one oral tablet.
• The ingredients act through different pathways: incretin hormone regulation and reduced liver glucose production.
• The stated indication is type 2 diabetes. This tablet is not intended to treat diabetic ketoacidosis.

Benefits

• Clinical studies of vildagliptin with metformin have shown improvements in measures of blood glucose control, including HbA1c, in people with type 2 diabetes.
• A combination tablet can reduce the number of separate tablets needed when both ingredients are prescribed at compatible strengths.
• The labelled 50 mg/1000 mg strength clearly identifies the amounts of the two active ingredients, allowing a prescriber to assess whether it fits an existing treatment regimen.

Possible Side Effects

• Digestive symptoms associated with metformin can include nausea, diarrhoea, abdominal discomfort, vomiting and reduced appetite. These often occur when treatment starts.
• Headache, dizziness or tremor may occur. A healthcare professional can assess persistent or troublesome symptoms.
• Low blood glucose is more likely when the combination is used with insulin or a sulfonylurea.
• Rare but serious problems associated with these ingredients include pancreatitis, liver injury, severe allergic reactions and lactic acidosis. Severe or persistent abdominal pain, yellowing of the skin or eyes, facial swelling, or marked weakness with breathing difficulties needs urgent medical assessment.

Precautions

• Kidney function needs assessment before and during treatment with metformin-containing medicines. Reduced kidney function can affect treatment suitability and increase the risk of lactic acidosis.
• Liver impairment, dehydration, severe infection and conditions that reduce oxygen supply to body tissues require medical review.
• Excessive alcohol consumption increases the risk of metformin-associated lactic acidosis.
• A history of pancreatitis or a serious reaction to either ingredient should be discussed with a healthcare professional before use.

Additional Precautions

• Blood glucose monitoring and periodic kidney and liver tests may be part of ongoing care.
• Pregnancy or breastfeeding calls for a review of diabetes treatment with a healthcare professional.
• Severe illness, dehydration or major surgery may affect whether metformin-containing treatment can continue temporarily.
• Tell the treating team about metformin before a scan involving iodinated contrast. They can advise whether treatment needs to be interrupted.
• Ask a pharmacist about product-specific inactive ingredients if you have an allergy or need to check the tablet’s composition.

Storage Instructions

• Follow the storage directions and expiry date printed on the supplied Vysov-M packaging.
• Keep the tablets in their original packaging and out of the reach of children.
• Avoid exposing the tablets to excessive heat or moisture. Ask a pharmacist if the pack has been damaged or the tablets appear altered.

How to Take

• Follow the directions supplied by the prescribing healthcare professional. The regimen depends on the person’s existing treatment, response and tolerability.
• Taking vildagliptin and metformin combinations with or just after food may reduce stomach symptoms associated with metformin.
• Check the supplied pack or ask a pharmacist for product-specific instructions, including whether the tablet may be split or crushed.
• Seek professional advice about a missed dose, an accidental extra dose or a planned change to other diabetes medicines.

Drug Interactions

• Insulin and sulfonylureas can increase the risk of low blood glucose when combined with vildagliptin and metformin.
• Some anti-inflammatory medicines, diuretics and other medicines that affect kidney function can increase risks associated with metformin.
• Corticosteroids and certain other medicines can raise blood glucose and affect diabetes control.
• Angiotensin-converting enzyme (ACE) inhibitors may increase the risk of angioedema when used with vildagliptin.
• Iodinated contrast agents used for some scans require special consideration because the tablet contains metformin. Give healthcare professionals a complete list of medicines and supplements.

Why Choose This Product?

• It brings vildagliptin and metformin together in one tablet when both are part of an appropriate prescribed regimen.
• Its stated strength specifies the amount of each active ingredient per tablet.
• The ingredient combination has clinical evidence supporting blood glucose improvement in type 2 diabetes. Whether this particular product is appropriate depends on an individual clinical assessment.

Frequently Asked Questions (FAQs)

What is Vysov-M 50/1000 Mg Tablet used for?

It is presented for blood glucose management in type 2 diabetes when vildagliptin and metformin are appropriate together.

What does 50/1000 mg mean?

It identifies 50 mg of vildagliptin and 1000 mg of metformin per tablet.

Is this tablet for type 1 diabetes?

No. The vildagliptin and metformin combination is used for type 2 diabetes and does not replace insulin for type 1 diabetes.

Can it cause low blood glucose?

The risk is higher when it is taken with insulin or a sulfonylurea. A healthcare professional can explain the risk within a specific regimen.

Can it cause stomach upset?

Yes. Metformin can cause nausea, diarrhoea and abdominal discomfort, particularly when treatment begins.

Why are kidney tests needed?

Kidney function helps determine whether metformin-containing treatment is appropriate and informs assessment of lactic acidosis risk.

What if I am pregnant or breastfeeding?

Discuss diabetes treatment with a healthcare professional, as the medicine plan may need review.

What should I mention before a scan?

Tell the imaging team that the tablet contains metformin, especially if iodinated contrast may be used.

Does the tablet replace diet and physical activity?

No. It is intended to be used within a broader type 2 diabetes management plan.

How should I store Vysov-M?

Follow the directions on the supplied pack and ask a pharmacist if they are unclear.

Related Products

• Vysov-M 50/500 Mg Tablet (Vildagliptin/Metformin)
• Vysov-M 50/1000 Mg Tablet (Vildagliptin/Metformin)
• Bromocriptine 2.5 mg Australia
• Miglitol 25 mg Australia
• Repaglinide 2 mg Australia
• Glimepiride 1 mg Australia